GAMMA Investing’s CorMedix CRMD Stock Holding History

GAMMA Investing’s Portfolio CRMD Stock Details CRMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$3.77K	Sell	489 -138	-22%	-$1.11K	﹤0.01%	3764
2026 Q2	$4.92K	Buy	627 +241	+62%	+$1.9K	﹤0.01%	3477
2026 Q1	$2.62K	Sell	386 -176	-31%	-$1.3K	﹤0.01%	3577
2025 Q4	$6.54K	Buy	562 +196	+54%	+$2.17K	﹤0.01%	3161
2025 Q3	$4.26K	Buy	366 +11	+3%	+$133	﹤0.01%	3240
2025 Q2	$4.37K	Buy	355 +228	+180%	+$2.52K	﹤0.01%	3176
2025 Q1	$782	Buy	+127	New	+$1.31K	﹤0.01%	3607

Other funds holding CRMD

HWAM

Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

FFA

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

MPWT

MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return

FFO

Fortitude Family Office Scottsdale, Arizona $586M AUM 20.58% 1-Year Est. Return

GAMMA Investing's CRMD Position: Q3 2026 in Review

GAMMA Investing reduced its CorMedix (CRMD) stake by 22% in Q3 2026, selling an estimated $1.11K and leaving 489 shares worth $3.77K. The position accounts for ﹤0.01% of the portfolio, ranked #3764.

GAMMA Investing first reported a position in CRMD in Q1 2025 and has held it in 7 quarters since. The position peaked at $6.54K in Q4 2025. 6 funds tracked by Wall St. Rank hold CRMD as of Q3 2026.

GAMMA Investing held 489 shares of CorMedix worth $3.77K as of Q3 2026.
GAMMA Investing sold 138 CorMedix shares in Q3 2026, an estimated $1.11K.
CorMedix made up ﹤0.01% of GAMMA Investing's portfolio in Q3 2026, its #3764 holding.
GAMMA Investing first reported a position in CorMedix in Q1 2025 and has held it in 7 quarters since.
GAMMA Investing's CorMedix position peaked at $6.54K in Q4 2025.
6 funds tracked by Wall St. Rank held CorMedix as of Q3 2026.

Based on GAMMA Investing's 13F filing for Q3 2026, filed 8 Oct 2026.